BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla ACTM, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmod N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ; Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut 2021;70:1266-74. [PMID: 33046558 DOI: 10.1136/gutjnl-2019-319129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Warrington JP, Drummond HA, Granger JP, Ryan MJ. Placental ischemia-induced increases in brain water content and cerebrovascular permeability: role of TNF-α. Am J Physiol Regul Integr Comp Physiol 2015;309:R1425-31. [PMID: 26400187 DOI: 10.1152/ajpregu.00372.2015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
4 Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth Outcomes in Children Fathered by Men Treated with Anti-TNF-α Agents Before Conception. American Journal of Gastroenterology 2016;111:1608-13. [DOI: 10.1038/ajg.2016.405] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
5 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 92] [Article Influence: 39.7] [Reference Citation Analysis]
6 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 189] [Article Influence: 32.0] [Reference Citation Analysis]
7 Winter R, Nørgård BM, Friedman S. Treatment of the Pregnant Patient with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:733-744. [PMID: 26658216 DOI: 10.1097/MIB.0000000000000625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 2021;19:1092-115. [PMID: 34288477 DOI: 10.1111/ddg.14507] [Reference Citation Analysis]
9 Pons M, Dougados M, Costedoat-Chalumeau N, Briot K, Goupille P, Roux C, Molto A. Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort. Joint Bone Spine 2021;88:105075. [PMID: 32947013 DOI: 10.1016/j.jbspin.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ross C, D'Souza R, Pagnoux C. Pregnancy Outcomes in Systemic Vasculitides. Curr Rheumatol Rep 2020;22:63. [PMID: 32845412 DOI: 10.1007/s11926-020-00940-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, Lynd LD, Marra CA, De Vera MA. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Ann Rheum Dis 2018;77:869-74. [PMID: 29496718 DOI: 10.1136/annrheumdis-2018-213023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
12 Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:414-7. [PMID: 27338778 DOI: 10.1136/annrheumdis-2016-209322] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 11.3] [Reference Citation Analysis]
13 Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) 2020;72:461-88. [PMID: 32090466 DOI: 10.1002/acr.24130] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
14 Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy. Clinical Gastroenterology and Hepatology 2016;14:234-241.e5. [DOI: 10.1016/j.cgh.2015.08.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
15 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58 [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
16 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
17 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 2016;60:29-32. [PMID: 26806369 DOI: 10.1016/j.reprotox.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
19 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 de Lima A, Zelinkova Z, van der Ent C, Steegers EA, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261-1268. [PMID: 25966992 DOI: 10.1136/gutjnl-2015-309321] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 10.1] [Reference Citation Analysis]
21 Isojima S, Miura Y, Saito M, Yajima N, Miwa Y, Kasama T. Serum anti-Müllerian hormone levels in women with rheumatoid arthritis during tumor necrosis factor-α inhibitor treatment: Exploratory research. Obstet Med 2019;12:186-9. [PMID: 31853259 DOI: 10.1177/1753495X18820471] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
24 Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-randone S, Matucci-cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 2016;45:519-32. [DOI: 10.1016/j.semarthrit.2015.10.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
25 Vashisht P, O'dell J. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert Opin Biol Ther 2017;17:989-99. [PMID: 28594252 DOI: 10.1080/14712598.2017.1340453] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
26 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clinic Rev Allerg Immunol 2017;53:40-53. [DOI: 10.1007/s12016-016-8596-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
27 Tsuda S, Sameshima A, Sekine M, Kawaguchi H, Fujita D, Makino S, Morinobu A, Murakawa Y, Matsui K, Sugiyama T, Watanabe M, Suzuki Y, Nagahori M, Murashima A, Atsumi T, Oku K, Mitsuda N, Takei S, Miyamae T, Takahashi N, Nakajima K, Saito S; for The Ministry of Health Labour and Welfare Working Group for “Guideline for The Treatment of Rheumatoid Arthritis or Inflammatory Bowel Disease Bearing Women in Child-bearing Age”. Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive study. Modern Rheumatology 2020;30:852-61. [DOI: 10.1080/14397595.2019.1661592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
28 Bröms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, Pedersen L, Schmitt-Egenolf M, Sørensen HT, Granath F. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020;29:316-27. [PMID: 32020767 DOI: 10.1002/pds.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
29 Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-18. [PMID: 28758274 DOI: 10.1002/pds.4261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
30 Williams M, Chakravarty EF. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy. Curr Opin Rheumatol. 2014;26:341-346. [PMID: 24663107 DOI: 10.1097/bor.0000000000000046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
32 Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 2017;76:38-52. [PMID: 27913060 DOI: 10.1016/j.jaut.2016.11.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
33 Park E, Kim H, Jung SM, Sung Y, Baek HJ, Lee J. The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. J Rheum Dis 2020;27:4. [DOI: 10.4078/jrd.2020.27.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
34 Armstrong AW, Aldredge L, Yamauchi PS. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. J Cutan Med Surg 2016;20:196-206. [PMID: 26712930 DOI: 10.1177/1203475415623508] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
35 De Lorenzo R, Ramirez GA, Punzo D, Lorioli L, Rovelli R, Canti V, Barera G, Rovere-Querini P. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res 2020;152:104583. [PMID: 31816434 DOI: 10.1016/j.phrs.2019.104583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
37 Prasad JD, Gunn KC, Davidson JO, Galinsky R, Graham SE, Berry MJ, Bennet L, Gunn AJ, Dean JM. Anti-Inflammatory Therapies for Treatment of Inflammation-Related Preterm Brain Injury. Int J Mol Sci 2021;22:4008. [PMID: 33924540 DOI: 10.3390/ijms22084008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 De Felice KM, Kane S. Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol 2021;148:661-7. [PMID: 34489011 DOI: 10.1016/j.jaci.2021.07.005] [Reference Citation Analysis]
40 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
41 Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to Infliximab During Pregnancy: Post-Marketing Experience. Drug Saf 2020;43:147-61. [PMID: 31677004 DOI: 10.1007/s40264-019-00881-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
42 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
43 Cunningham MW, Jayaram A, Deer E, Amaral LM, Vaka VR, Ibrahim T, Cornelius DC, LaMarca B. Tumor necrosis factor alpha (TNF-α) blockade improves natural killer cell (NK) activation, hypertension, and mitochondrial oxidative stress in a preclinical rat model of preeclampsia. Hypertens Pregnancy 2020;39:399-404. [PMID: 32646252 DOI: 10.1080/10641955.2020.1793999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Cordero-coma M, Salazar-méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opinion on Drug Safety 2015;14:1071-86. [DOI: 10.1517/14740338.2015.1044969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher‐stine L, Crow‐hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D'anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020;72:529-56. [DOI: 10.1002/art.41191] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 39.0] [Reference Citation Analysis]
46 Góralczyk A, Kolossa K, Waszczak-Jeka M, Adamczak R, Jeka S. The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation. Postepy Dermatol Alergol 2020;37:306-12. [PMID: 32774212 DOI: 10.5114/ada.2020.96294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
47 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
48 Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810. [PMID: 26888948 DOI: 10.1136/annrheumdis-2015-208840] [Cited by in Crossref: 445] [Cited by in F6Publishing: 363] [Article Influence: 74.2] [Reference Citation Analysis]
49 Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2020;59:1808-17. [PMID: 32118278 DOI: 10.1093/rheumatology/keaa064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
50 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. J Dtsch Dermatol Ges 2021;19:1092-117. [PMID: 34288473 DOI: 10.1111/ddg.14507_g] [Reference Citation Analysis]
51 Ren Z, Cui N, Zhu M, Khalil RA. TNFα blockade reverses vascular and uteroplacental matrix metalloproteinases imbalance and collagen accumulation in hypertensive pregnant rats. Biochem Pharmacol 2021;193:114790. [PMID: 34600915 DOI: 10.1016/j.bcp.2021.114790] [Reference Citation Analysis]
52 Knickelbein JE, Armbrust KR, Kim M, Sen HN, Nussenblatt RB. Pharmacologic Treatment of Noninfectious Uveitis. Handb Exp Pharmacol 2017;242:231-68. [PMID: 27848029 DOI: 10.1007/164_2016_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
53 Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med 2020;35:41-59. [PMID: 31935319 DOI: 10.3904/kjim.2019.411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Kanis SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, van der Woude CJ. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. J Crohns Colitis 2018;12:939-47. [PMID: 29771301 DOI: 10.1093/ecco-jcc/jjy058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
55 Hunt N, Talabi MB. Family Planning and Rheumatoid Arthritis. Curr Rheumatol Rep 2019;21. [DOI: 10.1007/s11926-019-0816-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
57 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
58 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
59 Uyaroglu OA, Seyhoglu E, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli AI, Kiraz S, Kalyoncu U. Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study. Rheumatol Int 2020;40:1501-7. [PMID: 31993731 DOI: 10.1007/s00296-020-04518-3] [Reference Citation Analysis]
60 Ergaz Z, Bar-Oz B, Vainer GW, Abu-Leil S, Simanovsky N, Diav-Citrin O. Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reprod Toxicol. 2014;50:1-3. [PMID: 25277314 DOI: 10.1016/j.reprotox.2014.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32:238-246. [PMID: 32205567 DOI: 10.1097/bor.0000000000000710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]